Suppr超能文献

肠道微生物组:“隐形器官”与草药及其衍生化合物在慢性代谢性疾病中的相互作用。

Gut Microbiome: The Interplay of an "Invisible Organ" with Herbal Medicine and Its Derived Compounds in Chronic Metabolic Disorders.

机构信息

Department of Diagnostics, College of Korean Medicine, Dongguk University, Dongguk-Ro 32, Goyang 10326, Korea.

Institute of Bioscience & Integrative Medicine, Daejeon University, 75, Daedeok-daero 176, Seo-gu, Daejeon 35235, Korea.

出版信息

Int J Environ Res Public Health. 2022 Oct 11;19(20):13076. doi: 10.3390/ijerph192013076.

Abstract

Resembling a concealed "organ" in a holobiont, trillions of gut microbes play complex roles in the maintenance of homeostasis, including participating in drug metabolism. The conventional opinion is that most of any drug is metabolized by the host and that individual differences are principally due to host genetic factors. However, current evidence indicates that only about 60% of the individual differences in drug metabolism are attributable to host genetics. Although most common chemical drugs regulate the gut microbiota, the gut microbiota is also known to be involved in drug metabolism, like the host. Interestingly, many traditional herbal medicines and derived compounds are biotransformed by gut microbiota, manipulating the compounds' effects. Accordingly, the gut microbiota and its specified metabolic pathways can be deemed a promising target for promoting drug efficacy and safety. However, the evidence regarding causality and the corresponding mechanisms concerning gut microbiota and drug metabolism remains insufficient, especially regarding drugs used to treat metabolic disorders. Therefore, the present review aims to comprehensively summarize the bidirectional roles of gut microbiota in the effects of herbal medicine in metabolic diseases to provide vital clues for guiding the clinical application of precision medicine and personalized drug development.

摘要

类似于共生体中的隐藏“器官”,数以万亿计的肠道微生物在维持体内平衡方面发挥着复杂的作用,包括参与药物代谢。传统观点认为,大多数药物都是由宿主代谢的,个体差异主要归因于宿主的遗传因素。然而,现有证据表明,药物代谢的个体差异只有约 60%归因于宿主遗传因素。虽然大多数常见的化学药物调节肠道微生物群,但肠道微生物群也像宿主一样参与药物代谢。有趣的是,许多传统草药和衍生化合物都被肠道微生物群生物转化,从而改变化合物的作用。因此,肠道微生物群及其特定的代谢途径可以被视为提高药物疗效和安全性的有希望的靶点。然而,关于肠道微生物群与药物代谢之间因果关系及其相应机制的证据仍然不足,特别是对于用于治疗代谢紊乱的药物。因此,本综述旨在全面总结肠道微生物群在草药治疗代谢性疾病中的双向作用,为指导精准医学和个性化药物开发的临床应用提供重要线索。

相似文献

1
Gut Microbiome: The Interplay of an "Invisible Organ" with Herbal Medicine and Its Derived Compounds in Chronic Metabolic Disorders.
Int J Environ Res Public Health. 2022 Oct 11;19(20):13076. doi: 10.3390/ijerph192013076.
2
Regulation of Gut Microbiota by Herbal Medicines.
Curr Drug Metab. 2024;25(2):110-127. doi: 10.2174/0113892002287336240328083220.
3
4
Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs?
J Ethnopharmacol. 2016 Feb 17;179:253-64. doi: 10.1016/j.jep.2015.12.031. Epub 2015 Dec 23.
5
The metabolic effect of gut microbiota on drugs.
Drug Metab Rev. 2020 Feb;52(1):139-156. doi: 10.1080/03602532.2020.1718691. Epub 2020 Mar 2.
6
The interplay between herbal medicines and gut microbiota in metabolic diseases.
Front Pharmacol. 2023 Mar 24;14:1105405. doi: 10.3389/fphar.2023.1105405. eCollection 2023.
7
The interaction between the gut Microbiota and herbal medicines.
Biomed Pharmacother. 2019 Oct;118:109252. doi: 10.1016/j.biopha.2019.109252. Epub 2019 Aug 23.
8
Phytotherapy of mood disorders in the light of microbiota-gut-brain axis.
Phytomedicine. 2023 Mar;111:154642. doi: 10.1016/j.phymed.2023.154642. Epub 2023 Jan 4.
9
Understanding the Molecular Mechanisms of the Interplay Between Herbal Medicines and Gut Microbiota.
Med Res Rev. 2017 Sep;37(5):1140-1185. doi: 10.1002/med.21431. Epub 2017 Jan 4.
10
Therapeutic mechanisms of traditional Chinese medicine to improve metabolic diseases via the gut microbiota.
Biomed Pharmacother. 2021 Jan;133:110857. doi: 10.1016/j.biopha.2020.110857. Epub 2020 Nov 13.

引用本文的文献

1
Gut microbiota and the "gut-liver-kidney axis" theory: from mechanisms to therapeutics.
Front Microbiol. 2025 Jun 19;16:1554458. doi: 10.3389/fmicb.2025.1554458. eCollection 2025.
4
Cardioprotective Role of against Trimethylamine-N-Oxide and Glucose Induced Stress in Rat Cardiomyocytes.
Cardiovasc Hematol Agents Med Chem. 2024;22(4):475-494. doi: 10.2174/0118715257270512231013064533.

本文引用的文献

2
Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine.
J Pharm Anal. 2022 Aug;12(4):541-555. doi: 10.1016/j.jpha.2021.10.003. Epub 2021 Oct 21.
3
Human Gut Microbiota and Drug Metabolism.
Microb Ecol. 2023 Jul;86(1):97-111. doi: 10.1007/s00248-022-02081-x. Epub 2022 Jul 23.
4
Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort.
Nat Genet. 2022 Feb;54(2):134-142. doi: 10.1038/s41588-021-00991-z. Epub 2022 Feb 3.
5
Machine Learning Predicts Drug Metabolism and Bioaccumulation by Intestinal Microbiota.
Pharmaceutics. 2021 Nov 25;13(12):2001. doi: 10.3390/pharmaceutics13122001.
6
Cytochrome P450 Enzymes and Drug Metabolism in Humans.
Int J Mol Sci. 2021 Nov 26;22(23):12808. doi: 10.3390/ijms222312808.
8
Quercetin and metabolic syndrome: A review.
Phytother Res. 2021 Oct;35(10):5352-5364. doi: 10.1002/ptr.7144. Epub 2021 Jun 8.
10
Pharmacokinetics and Excretion of Berberine and Its Nine Metabolites in Rats.
Front Pharmacol. 2021 Jan 15;11:594852. doi: 10.3389/fphar.2020.594852. eCollection 2020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验